FXYD2 and central nervous system cancer: FXYD2 mRNA expression was not associated with sex (P = 0.657), age (P = 1.000), methylation of MGMT (P = 0.453) or radiotherapy or chemotherapy history (P = 1.000, P = 0.680, respectively) in glioma patients.